Japan's top drugmaker appoints first foreign boss

Japan's top drugmaker said Saturday it had picked a GlaxoSmithKline executive as its next president in a rare example of overseas head-hunting by a major Japanese firm.

The board of directors at Takeda Pharmaceutical, which has been active in foreign acquisitions in recent years, approved 47-year-old French Christophe Weber, as and candidate as the next chief executive.

He will be the first non-Japanese chief in 230 years of history at the company based in western Japan's Osaka.

Weber will join Takeda to take the role of chief operating officer by April 2014 and is expected to become president upon approval at a general meeting of shareholders in June, Takeda said in a statement.

Current president and chief executive Yasuchika Hasegawa is expected to become chairman and chief executive.

"We have extremely high expectations for Mr Weber's contributions to further enhance and accelerate the implementation of Takeda's global strategy," Hasegawa said in the statement.

Weber, educated at the University of Lyon, has held various positions at GSK in Europe, United States and the Asia-Pacific region.

Takeda operates in more than 70 countries after its 2011 acquisition of major Swiss rival Nycomed for $14 billion.

There are only a handful of foreign chiefs at leading Japanese companies. Carlos Ghosn, the of French auto group Renault who also heads Nissan Motor, is one of the most prominent.

add to favorites email to friend print save as pdf

Related Stories

Japanese firm buys US pharmaceutical company

Oct 05, 2012

(AP)—A Japanese pharmaceutical company is acquiring LigoCyte Pharmaceuticals in a $60 million deal to expand its vaccine division, Takeda Pharmaceutical Co. announced.

US drug firm Mylan to buy Indian firm for $1.6 bn

Feb 27, 2013

US generic drugs specialist Mylan said Thursday it would buy a unit of India's pharma firm Strides Arcolab for $1.6 billion, boosting its presence in the high-growth injectable drugs market.

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments